Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the American Heart Association
Cardiovascular disease remains the leading cause of death in patients with diabetes.
Cardiovascular disease in diabetes is multifactorial, and control of the cardiovascular risk …
Cardiovascular disease in diabetes is multifactorial, and control of the cardiovascular risk …
Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network …
Objective To evaluate sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-
like peptide-1 (GLP-1) receptor agonists in patients with type 2 diabetes at varying …
like peptide-1 (GLP-1) receptor agonists in patients with type 2 diabetes at varying …
Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association
Cardiorenal syndrome encompasses a spectrum of disorders involving both the heart and
kidneys in which acute or chronic dysfunction in 1 organ may induce acute or chronic …
kidneys in which acute or chronic dysfunction in 1 organ may induce acute or chronic …
Basic mechanisms of diabetic heart disease
Diabetes mellitus predisposes affected individuals to a significant spectrum of
cardiovascular complications, one of the most debilitating in terms of prognosis is heart …
cardiovascular complications, one of the most debilitating in terms of prognosis is heart …
Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America: this statement does not …
Type 2 diabetes mellitus is a risk factor for incident heart failure and increases the risk of
morbidity and mortality in patients with established disease. Secular trends in the …
morbidity and mortality in patients with established disease. Secular trends in the …
Cardiac late sodium channel current is a molecular target for the sodium/glucose cotransporter 2 inhibitor empagliflozin
K Philippaert, S Kalyaanamoorthy, M Fatehi, W Long… - Circulation, 2021 - Am Heart Assoc
Background: SGLT2 (sodium/glucose cotransporter 2) inhibitors exert robust
cardioprotective effects against heart failure in patients with diabetes, and there is intense …
cardioprotective effects against heart failure in patients with diabetes, and there is intense …
Insulin resistance and atherosclerosis: implications for insulin-sensitizing agents
A Di Pino, RA DeFronzo - Endocrine reviews, 2019 - academic.oup.com
Patients with type 2 diabetes mellitus (T2DM) are at high risk for macrovascular
complications, which represent the major cause of mortality. Despite effective treatment of …
complications, which represent the major cause of mortality. Despite effective treatment of …
Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials
Despite current established therapy, heart failure (HF) remains a leading cause of
hospitalization and mortality worldwide. Novel therapeutic targets are therefore needed to …
hospitalization and mortality worldwide. Novel therapeutic targets are therefore needed to …
Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality …
Importance The comparative clinical efficacy of sodium-glucose cotransporter 2 (SGLT-2)
inhibitors, glucagon-like peptide 1 (GLP-1) agonists, and dipeptidyl peptidase 4 (DPP-4) …
inhibitors, glucagon-like peptide 1 (GLP-1) agonists, and dipeptidyl peptidase 4 (DPP-4) …
Cardiovascular effects of new oral glucose-lowering agents: DPP-4 and SGLT-2 inhibitors
AJ Scheen - Circulation research, 2018 - Am Heart Assoc
Cardiovascular disease (CVD) is a major challenge in the management of type 2 diabetes
mellitus. Glucose-lowering agents that reduce the risk of major cardiovascular events would …
mellitus. Glucose-lowering agents that reduce the risk of major cardiovascular events would …